L-Citrulline

TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials today announced it has signed a contract with Asklepion Pharmaceuticals to deploy its NetraAI platform to analyze results from its pivotal Phase III pediatric clinical trial. The agreement covers the application of NetraAI’s advanced AI technology to analyze patient data from Asklepion’s CIT-003-01 study, which evaluated the efficacy of intravenous L-citrulline for preventing acute lung injury in children undergoing cardiopulmonary bypass surgery for congenital heart defects. Asklepion is deeply focused on translating science into meaningful therapies for children. By incorporating NetraMark’s AI analytics into their trial framework, they aim to enhance their ability to demonstrate the benefits of L-citrulline in specific patient subgroups. This approach reflects Asklepion’s ongoing pursuit of excellence in both science and strategy. By leveraging explainable AI and generative modeling, NetraAI seeks to enable precision trial optimization by delivering actionable insights that can enhance patient stratification and improve study outcomes. “Asklepion’s decision to engage NetraMark reflects a forward-thinking commitment to innovation in trial design,” said Josh Spiegel, President of NetraMark. “We are proud to bring our AI-driven capabilities to a program with such clinical importance and look forward to delivering insights that can optimize patient selection and study outcomes.” “We are committed to pushing the boundaries of pediatric drug development, and NetraMark’s technology offers a compelling path forward,” said Mr. Jeff Courtney, Chief Executive Officer at Asklepion Pharmaceuticals. “By integrating NetraAI’s explainable AI based analytics into our late phase study, we hope to uncover meaningful insights that sharpen our understanding of L-citrulline,” as stated by Dr. Gurdyal Kalsi, Chief Medical Officer at Asklepion Pharmaceuticals. “This partnership underscores our belief in the power of innovation to accelerate safer, more effective treatments for children.” NetraMark’s analysis will focus on identifying responder personas—subpopulations of patients who are most likely to benefit from treatment. These insights will inform study designs for future L-citrulline development. About NetraMarkNetraMark is a company focused on being a leader in the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the Pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. For further details on the Company please see the Company’s publicly available documents filed on the System for Electronic Document Analysis and Retrieval+ (SEDAR+). For more NetraMark information, see the company’s website and follow NetraMark on LinkedIn. Forward-Looking StatementsThis press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation including statements regarding the capabilities of Netra AI to deliver actionable insights to enhance patient stratification and improve study outcomes, the ability of Netra AI to uncover meaningful insights for Asklepion that sharpen understanding of L-citrulline and inform study designs for future L-citrulline development which are based upon NetraMark’s current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as “expect”, “likely”, “may”, “will”, “should”, “intend”, “anticipate”, “potential”, “proposed”, “estimate” and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions “may”, “would” or “will” happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. The forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results of the Company or industry results to differ materially from future results, performance or achievements. Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, NetraMark does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for NetraMark to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements as set out in the materials we file with applicable Canadian securities regulatory authorities on SEDAR+ at www.sedarplus.ca including our Management’s Discussion and Analysis for the year ended September 30, 2024. These risk factors and other factors could cause actual events or results to differ materially from those described in any forward-looking information. The CSE does not accept responsibility for the adequacy or accuracy of this release. Contact Information:Swapan Kakumanu - CFO | swapan@netramark.com | 403-681-2549

The Energy Drink Formula Unleashes Unique Levels of Energy Whilst Avoiding Sugar Crashes and Unhealthy Ingredients FORT LAUDERDALE, Fla., Oct. 5, 2023 /PRNewswire/ -- The modern, remote-first work world may not have a consistent nine-to-five rhythm anymore. But that doesn't change the fact that people are still putting a lot of time into working their jobs. The Bureau of Labor Statistics reports that the average American worker clocks in at just over eight hours of labor per day (8.01, to be precise). That means, no matter when those work hours take place, they're going to extend over a significant portion of an individual's daily schedule. It also means it will involve a slump in energy and productivity at some point along the way. "Midday slumps may not always happen in the early afternoon anymore," says Gavin Jacono, founder of Bizz Energy, "But they happen at some point — and on a regular basis. If you start work at four in the morning, chances are you're going to lag after breakfast or in the late morning. If you start at noon, you'll feel tired before dinner." Northwestern Medicine points out that the biggest reason for this energy slump is that it's a predictable part of every individual's circadian cycle. However, the medical site adds that things like sleep disorders, stress, and even poor eating habits can also contribute to a slowdown in the middle of the workday. When that happens, many people turn to energy drinks as a solution — but Jacono points out that traditional energy drink formulas don't really solve the problem. "Those classic formulas use sugar, high fructose corn syrup, or aspartame. They give you a quick boost, but it's often followed by a crash — usually before your work day ends, which only means you're kicking the productivity issue down the road. And your body has to work through all of those unhealthy chemicals and additives, too. That's why we created Bizz Energy. To turn unhealthy, short-term energy drinks into healthy, long-term productivity and health solutions." Bizz Energy replaces unwanted ingredients with healthy alternatives. Each 12 oz can contains a clean shot of 200 mg of caffeine along with a punchy nutritional combination called the SuperTurk® blend. This includes an innovative soluble form of Turkesterone along with creatine, essential amino acids, L-citrulline, L-theanine, L-carnitine, niacin, and biotin. The result of this revolutionary combination is an energy drink that doubles as a nutritional supplement. It helps boost energy without a sugar crash while also stimulating metabolism and helping build muscle and strength. This makes it a clean, mean way to beat a midday slump — no matter when it might take place. About Bizz Energy Bizz Energy was founded by Gavin Jacono. The fitness and nutrition fanatic hails from New York City and is obsessed with boxing, weightlifting, and soccer. As an aspiring 17-year-old entrepreneur, Jacono launched Bizz Energy as a way to create the ultimate energy drink he had always wanted to fuel his athletic pursuits. Along with a potent dose of caffeine, the Bizz Energy formula taps into a unique form of soluble Turkesterone. It is delicious, clean, and effective. Learn more at bizzenergy.com. Media Contact: Gavin Jacono 516-637-8701 [email protected] SOURCE Bizz Energy